Synthesis and Preclinical Evaluation of Medications to Treat Substance Use Disorders (SUDs) (R01)
Post Date
May 15th 2012
Application Due Date
August 15th 2012
Funding Opportunity Number
RFA-DA-13-004
CFDA Number(s)
93.279
Funding Instrument Type(s)
Grant
Funding Activity Categories
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Funding
-
Estimated Total Funding:
$2500000
-
Award Range:
$None - $None
Grant Description
The National Institute on Drug Abuse (NIDA) is soliciting grant (R01) applications to support the synthesis and preclinical evaluation of new molecular entities as potential treatments for Substance Use Disorders (SUDs). Responsive applications may include synthesis, identification, optimization and preclinical efficacy and/or safety assessment of lead compounds. Applications must provide timelines and decision-trees with go/no-go criteria to advance or discontinue testing a compound. Possible new molecular entities include, but are not limited to, small molecules, enzymes, antibodies, and vaccines. The goal is to identify candidate compounds and advance them towards Investigational New Drug (IND) submission.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
-
More Information:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-13-004.html
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: